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The results of the first clinical experience with cell transplantationwere reported to the American Heart Association in November 2000by Menasche and associates1 of Paris. A 72-year-old man who hada transmural myocardial infarction with an ejection fraction of 21%received skeletal myoblasts implanted into the infarct region at thetime of coronary bypass surgery. Five months later, he had recovered
from the operation, and perfusion and function of the infarct region had improved,
perhaps related to the cell transplantation. This initial case report provides hope that
the damage from an extensive myocardial infarction may be reversed. Coronary
bypass surgery is frequently inadequate to restore function in patients who have few
viable surviving myocytes in the infarct region. Cell transplantation offers the
promise of restoring function in these unfortunate patients.2-4 However, the era of
cell transplantation has only begun. Major questions remain. What type of cell is
appropriate for autotransplantation? When should these cells be delivered and by
what route? What is the efficacy of cell transplantation relative to other medical and
surgical treatments? What outcome measures can be used to compare alternative
treatments in blinded randomized trials?
A number of research groups have implanted heart cells,2 skeletal muscle cells,3
smooth muscle cells,4 and bone marrow stem cells5 into injured myocardium. The
implanted cells engrafted within the injured region and improved regional perfusion,
wall thickening, and wall motion, as well as global function. The animal studies and
the initial clinical experience suggest that cell transplantation has great potential, but
the mechanism of benefit remains incompletely characterized. Histologic studies
suggest that the engrafted cells induce angiogenesis. The cells orient against the
cardiac stress and prevent thinning and dilatation of the injured region. Careful
sonometric studies performed at Duke University suggest that engrafted skeletal
myoblasts altered the elasticity of the scarred region.3 The altered elastic properties
of the engrafted region and the angiogenesis that is induced may have prevented
cardiac remodeling, avoiding cardiac thinning and dilatation and congestive heart
failure.
The benefits of cell transplantation have been shown without demonstrating that
the implanted cells beat synchronously with the native heart. Heart cells implanted
into normal myocardium have been shown to communicate with native cardiomy-
ocytes by intercalated disks,6 but heart cells implanted into an infarct region have
not been shown to communicate with the recipient cardiomyocytes.2 Skeletal
myocytes implanted into an infarct region appear to adopt a cardiac cell-like
morphology, but electrochemical connections permitting synchronous contractility
have not been demonstrated.7 Smooth muscle cells proliferate and hypertrophy in
response to the stress of cardiac contractions, but do not beat.4 Mesenchymal stem
cells derived from adult bone marrow can differentiate toward a cardiac phenotype
and have been induced to beat synchronously in vitro.8 These cells communicate
with the normal cardiomyocytes by intercalated disks. However, mesenchymal cells
implanted in an infarct region did not beat synchronously with the heart.9 Future
studies should establish whether the implanted cells assume a cardiac morphology,
whether they communicate with the normal myocardium, and whether they beat
synchronously with the heart. Sonomicrometry permits an excellent assessment of
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regional dimensions and thickening, but sonomicrometry
cannot differentiate implanted from hibernating native cells
in the infarct region. We used 99m technetium-Sestambi
single-photon emission tomography to evaluate perfusion
and wall motion in the infarct zone. Echocardiography
offers the hope of detecting synchronous contraction of the
transplanted cells.
In this issue of the Journal, Rajnoch and colleagues10
present an interesting study of skeletal myoblast implanta-
tion after cardiac injury. Their study suggests that satellite
cell implantation improved both regional and global func-
tion. In most animal models used to evaluate cell transplan-
tation, cardiac injury is induced either by coronary ligation
or by cryoinjury resulting in cardiomyocyte loss and remod-
eling of the infarct region. Remodeling has been uniformly
associated with thinning and dilatation of the infarct region
and deterioration of global function. In the sheep model
used in this study, the myocardium was injured by in-
tramyocardial injection of a snake cardiotoxin. Unfortu-
nately, the sequence of events after the injection of the toxin
was not well documented in the control group. In some
control animals, the injured region thinned and the heart
dilated. In the transplant group, the heart did not dilate and
global function did not deteriorate. However, a blinded
comparison between control and transplant animals is nec-
essary to accurately conclude that cell transplantation im-
proved global or regional function.
Regional ventricular function is extremely difficult to
assess. The authors of this study used color kinesis echo-
cardiography, which tracks regional movement. Unfortu-
nately, cardiac motion may alter the echo region interro-
gated, and changes in preload, afterload, and ventricular
shape and size can influence the measurements. These vari-
ables may have differed between control and treatment
animals. Therefore, the authors have not convincingly dem-
onstrated a difference in regional contractility, although
their results are suggestive.
In summary, cell transplantation offers the promise of
restoring regional function for patients who have had an
extensive myocardial infarction. The recent report from
Paris demonstrates the clinical feasibility of this new sur-
gical technique. Future studies will need to establish the
relative efficacy of this approach. Carefully conducted clin-
ical trials using sensitive and specific end points may help
us to determine the relative value of cell transplantation.
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